DECIDE Modalities Beneficial for African-Americans With T2DM

Share this content:
DECIDE Modalities Beneficial for African-Americans With T2DM
DECIDE Modalities Beneficial for African-Americans With T2DM

THURSDAY, Nov. 17, 2016 (HealthDay News) -- For African-Americans with type 2 diabetes, the Decision-making Education for Choices In Diabetes Everyday (DECIDE) program is beneficial, according to a study published online Nov. 14 in Diabetes Care.

Stephanie L. Fitzpatrick, Ph.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues compared the effectiveness of DECIDE with enhanced usual care (UC) among 182 urban African-Americans with type 2 diabetes with a suboptimal cardiovascular disease risk factor profile. Participants were randomly allocated to DECIDE Self-Study (46 participants), DECIDE Individual (45 participants), DECIDE Group (46 participants), or Enhanced UC (45 participants) for 18 to 20 weeks.

The researchers observed no significant difference in clinical outcomes for DECIDE modalities and Enhanced UC at six months after the intervention. For participants with hemoglobin A1c ≥7.5 percent at baseline, there was a decrease with each DECIDE modality at one week post-intervention (P < 0.05), and a decrease at six months after the intervention in Self-Study only (P < 0.05). In Self-Study and Group, there was a significant reduction in systolic blood pressure at six months after the intervention. Significant decreases were seen in low-density lipoprotein in Self-Study, Individual, and Enhanced UC; Self-Study had an increase in high-density lipoprotein at six months after the intervention.

"DECIDE modalities showed benefits after intervention," the authors write. "Self-Study demonstrated robust improvements across clinical and behavioral outcomes, suggesting program suitability for broader dissemination to populations with similar educational and literacy levels."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »